YTSN Stock Overview

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. More details

YTSN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 0.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Kuros Biosciences AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kuros Biosciences
Historical stock prices
Current Share Price	CHF 25.44
52 Week High	CHF 31.16
52 Week Low	CHF 24.32
Beta	0.72
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	YTSN	DE Biotechs	DE Market
7D	3.2%	-0.8%	-1.4%
1Y	n/a	-13.7%	13.5%

Return vs Industry: Insufficient data to determine how YTSN performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how YTSN performed against the German Market.

Price Volatility

Is YTSN's price volatile compared to industry and market?
YTSN volatility
YTSN Average Weekly Movement	n/a
Biotechs Industry Average Movement	4.9%
Market Average Movement	6.6%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: YTSN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine YTSN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	122	Chris Fair	kurosbio.com

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.

Kuros Biosciences AG Fundamentals Summary

How do Kuros Biosciences's earnings and revenue compare to its market cap?
YTSN fundamental statistics
Market cap	€1.00b
Earnings (TTM)	-€3.99m
Revenue (TTM)	€81.03m

12.4x

P/S Ratio

-252.2x

P/E Ratio

Is YTSN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
YTSN income statement (TTM)
Revenue	CHF 75.56m
Cost of Revenue	CHF 8.42m
Gross Profit	CHF 67.13m
Other Expenses	CHF 70.85m
Earnings	-CHF 3.72m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 13, 2025

Earnings per share (EPS)	-0.097
Gross Margin	88.85%
Net Profit Margin	-4.92%
Debt/Equity Ratio	0%

How did YTSN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 04:58
End of Day Share Price	2025/05/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Laura Pfeifer-Rossi	Bank am Bellevue
Olav Zilian	Mirabaud Securities Limited
Dylan van Haaften	NIBC Bank N.V.